Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis

Siddharth Singh, Edward Vincent Loftus, Jr, Jayant A. Talwalkar

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The course of inflammatory bowel disease (IBD) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complex, with several IBD-, PSC-, and transplant-related factors interplaying with each other. Approximately one-third of patients with known IBD improve, and one-third paradoxically worsen, after LT for PSC. Active IBD, discontinuation of 5-aminosalicylates (5-ASA) at time of LT and tacrolimus-based immunosuppression may be associated with an unfavorable course of IBD after LT. Approximately 14-30% patients with PSC may develop de novo IBD 10 years after LT. LT confers a high risk of pouchitis after ileal pouch-anal anastomosis, although it may not be higher than baseline rates for PSC patients. The risk of colorectal cancer continues to be high after LT for PSC, and is higher in this cohort of patients with PSC-IBD, compared with patients undergoing LT for other indications. IBD does not adversely affect patient survival after LT, although the risk of recurrent PSC in the allograft may be higher in patients with IBD and an intact colon at time of LT. Standard therapy with 5-ASA and/or azathioprine may be appropriate for treatment of active IBD after LT and maintenance of remission. Anti-tumor necrosis factor-α agents are effective, but should be used with caution because of high risk of adverse events. The management of IBD after LT requires close coordination between transplant hepatologists and IBD experts.

Original languageEnglish (US)
Pages (from-to)1417-1425
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume108
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Sclerosing Cholangitis
Inflammatory Bowel Diseases
Liver Transplantation
Mesalamine
Pouchitis
Transplants
Colonic Pouches
Azathioprine
Tacrolimus
Immunosuppression
Allografts
Colorectal Neoplasms
Colon
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. / Singh, Siddharth; Loftus, Jr, Edward Vincent; Talwalkar, Jayant A.

In: American Journal of Gastroenterology, Vol. 108, No. 9, 09.2013, p. 1417-1425.

Research output: Contribution to journalArticle

@article{025c954d6f0d4f43b59491e78591bbd8,
title = "Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis",
abstract = "The course of inflammatory bowel disease (IBD) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complex, with several IBD-, PSC-, and transplant-related factors interplaying with each other. Approximately one-third of patients with known IBD improve, and one-third paradoxically worsen, after LT for PSC. Active IBD, discontinuation of 5-aminosalicylates (5-ASA) at time of LT and tacrolimus-based immunosuppression may be associated with an unfavorable course of IBD after LT. Approximately 14-30{\%} patients with PSC may develop de novo IBD 10 years after LT. LT confers a high risk of pouchitis after ileal pouch-anal anastomosis, although it may not be higher than baseline rates for PSC patients. The risk of colorectal cancer continues to be high after LT for PSC, and is higher in this cohort of patients with PSC-IBD, compared with patients undergoing LT for other indications. IBD does not adversely affect patient survival after LT, although the risk of recurrent PSC in the allograft may be higher in patients with IBD and an intact colon at time of LT. Standard therapy with 5-ASA and/or azathioprine may be appropriate for treatment of active IBD after LT and maintenance of remission. Anti-tumor necrosis factor-α agents are effective, but should be used with caution because of high risk of adverse events. The management of IBD after LT requires close coordination between transplant hepatologists and IBD experts.",
author = "Siddharth Singh and {Loftus, Jr}, {Edward Vincent} and Talwalkar, {Jayant A.}",
year = "2013",
month = "9",
doi = "10.1038/ajg.2013.163",
language = "English (US)",
volume = "108",
pages = "1417--1425",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis

AU - Singh, Siddharth

AU - Loftus, Jr, Edward Vincent

AU - Talwalkar, Jayant A.

PY - 2013/9

Y1 - 2013/9

N2 - The course of inflammatory bowel disease (IBD) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complex, with several IBD-, PSC-, and transplant-related factors interplaying with each other. Approximately one-third of patients with known IBD improve, and one-third paradoxically worsen, after LT for PSC. Active IBD, discontinuation of 5-aminosalicylates (5-ASA) at time of LT and tacrolimus-based immunosuppression may be associated with an unfavorable course of IBD after LT. Approximately 14-30% patients with PSC may develop de novo IBD 10 years after LT. LT confers a high risk of pouchitis after ileal pouch-anal anastomosis, although it may not be higher than baseline rates for PSC patients. The risk of colorectal cancer continues to be high after LT for PSC, and is higher in this cohort of patients with PSC-IBD, compared with patients undergoing LT for other indications. IBD does not adversely affect patient survival after LT, although the risk of recurrent PSC in the allograft may be higher in patients with IBD and an intact colon at time of LT. Standard therapy with 5-ASA and/or azathioprine may be appropriate for treatment of active IBD after LT and maintenance of remission. Anti-tumor necrosis factor-α agents are effective, but should be used with caution because of high risk of adverse events. The management of IBD after LT requires close coordination between transplant hepatologists and IBD experts.

AB - The course of inflammatory bowel disease (IBD) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complex, with several IBD-, PSC-, and transplant-related factors interplaying with each other. Approximately one-third of patients with known IBD improve, and one-third paradoxically worsen, after LT for PSC. Active IBD, discontinuation of 5-aminosalicylates (5-ASA) at time of LT and tacrolimus-based immunosuppression may be associated with an unfavorable course of IBD after LT. Approximately 14-30% patients with PSC may develop de novo IBD 10 years after LT. LT confers a high risk of pouchitis after ileal pouch-anal anastomosis, although it may not be higher than baseline rates for PSC patients. The risk of colorectal cancer continues to be high after LT for PSC, and is higher in this cohort of patients with PSC-IBD, compared with patients undergoing LT for other indications. IBD does not adversely affect patient survival after LT, although the risk of recurrent PSC in the allograft may be higher in patients with IBD and an intact colon at time of LT. Standard therapy with 5-ASA and/or azathioprine may be appropriate for treatment of active IBD after LT and maintenance of remission. Anti-tumor necrosis factor-α agents are effective, but should be used with caution because of high risk of adverse events. The management of IBD after LT requires close coordination between transplant hepatologists and IBD experts.

UR - http://www.scopus.com/inward/record.url?scp=84883743110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883743110&partnerID=8YFLogxK

U2 - 10.1038/ajg.2013.163

DO - 10.1038/ajg.2013.163

M3 - Article

C2 - 23896954

AN - SCOPUS:84883743110

VL - 108

SP - 1417

EP - 1425

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -